- Home
- FOF vs LRMR Comparison
FOF vs LRMR Comparison
Compare FOF & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOF
- LRMR
- Stock Information
- Founded
- FOF 2006
- LRMR N/A
- Country
- FOF United States
- LRMR United States
- Employees
- FOF N/A
- LRMR N/A
- Industry
- FOF Investment Managers
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- FOF Finance
- LRMR Health Care
- Exchange
- FOF Nasdaq
- LRMR Nasdaq
- Market Cap
- FOF 362.3M
- LRMR 360.3M
- IPO Year
- FOF N/A
- LRMR N/A
- Fundamental
- Price
- FOF $13.03
- LRMR $3.88
- Analyst Decision
- FOF
- LRMR Strong Buy
- Analyst Count
- FOF 0
- LRMR 7
- Target Price
- FOF N/A
- LRMR $16.71
- AVG Volume (30 Days)
- FOF 58.7K
- LRMR 1.9M
- Earning Date
- FOF 01-01-0001
- LRMR 11-14-2025
- Dividend Yield
- FOF 9.07%
- LRMR N/A
- EPS Growth
- FOF N/A
- LRMR N/A
- EPS
- FOF N/A
- LRMR N/A
- Revenue
- FOF N/A
- LRMR N/A
- Revenue This Year
- FOF N/A
- LRMR N/A
- Revenue Next Year
- FOF N/A
- LRMR N/A
- P/E Ratio
- FOF N/A
- LRMR N/A
- Revenue Growth
- FOF N/A
- LRMR N/A
- 52 Week Low
- FOF $9.59
- LRMR $1.61
- 52 Week High
- FOF $11.75
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- FOF 50.07
- LRMR 43.33
- Support Level
- FOF $12.86
- LRMR $3.87
- Resistance Level
- FOF $13.16
- LRMR $4.50
- Average True Range (ATR)
- FOF 0.14
- LRMR 0.29
- MACD
- FOF -0.00
- LRMR -0.05
- Stochastic Oscillator
- FOF 47.29
- LRMR 15.58
About FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.